Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

Optimizing Biosimilar Treatment Strategies in Bone Health

May 17th 2024

Colin C. Edgerton, MD, discusses key considerations for utilizing biosimilars in the bone health treatment landscape.

The Top 5 Biosimilar Articles for the Week of May 13

May 17th 2024

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of May 13, 2024.

Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings

May 16th 2024

By Skylar Jeremias

Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.

Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars

May 15th 2024

By Skylar Jeremias

At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.

Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches

May 14th 2024

By Skylar Jeremias

The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.

Survey Finds Korean Oncologists Trust Biosimilars But Prescribe Originators More

May 13th 2024

By Cameron Santoro

A Korean survey found that while most oncologists believe biosimilars are just as safe and effective as originator drugs, they often prescribe the originators due to factors like lack of patient trust in biosimilars and lower than expected cost savings.

Jeffrey Casberg Predicts Generic, Biosimilar Competition in the Pharmaceutical Market

May 12th 2024

By Cameron Santoro

Jeffrey Casberg, RPh, MS, examines upcoming generic and biosimilar competition in the pharmaceutical industry, showcasing certain drugs that will face competition soon.

Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar

May 11th 2024

By Deana Ferreri, PhD

In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.

Resources for Patients and Providers on Adalimumab Biosimilars

May 10th 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Expert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.

The Role of Nurses and Support Personal in Educating Patient on Adalimumab Biosimilars

May 10th 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Providers in inflammatory diseases discuss the instrumental role nurses and support staff play in educating patients on adalimumab biosimilars.